ERIS — Eris Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for Eris Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	12,119	13,470	16,851	20,091	28,936
Cost of Revenue
Gross Profit	9,649	10,807	13,192	16,062	21,797
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	8,243	9,225	12,635	15,148	21,919
Operating Profit	3,876	4,245	4,217	4,944	7,017
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,945	4,422	4,046	4,312	4,889
Provision for Income Taxes
Net Income After Taxes	3,551	4,058	3,742	3,971	3,747
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,551	4,061	3,822	3,920	3,518
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,551	4,061	3,822	3,920	3,518
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	26.1	30.2	28.2	28.9	25.8
Dividends per Share